Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma
暂无分享,去创建一个
Qianxue Chen | Shenqi Zhang | Ji’an Yang | Lun Gao | Liquan Wu | Qian Sun | Yixuan Wang | Liguo Ye | Jiayang Cai | Zhang Ye | Shi’ao Tong | Yuanyuan Hu
[1] Yuan Xie,et al. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis , 2022, Cell Death & Disease.
[2] E. Bongarzone,et al. Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy , 2022, Frontiers in Oncology.
[3] Yang Xu,et al. TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway , 2022, Translational oncology.
[4] Marek J. Łos,et al. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma , 2022, International journal of molecular sciences.
[5] Michael R Hamblin,et al. Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy. , 2022, Cytokine & growth factor reviews.
[6] Shengbiao Li,et al. RSL3 Drives Ferroptosis through NF-κB Pathway Activation and GPX4 Depletion in Glioblastoma , 2021, Oxidative medicine and cellular longevity.
[7] N. Bernardes,et al. p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[8] Zhiming Liu,et al. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma , 2021, Cell Death & Disease.
[9] Junjie Chen,et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation , 2021, Nature Communications.
[10] M. Conrad,et al. The Metabolic Underpinnings of Ferroptosis. , 2020, Cell metabolism.
[11] H. Friedman,et al. Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.
[12] P. Shang,et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. , 2020, Cancer letters.
[13] Wei-Hwa Lee,et al. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial–Mesenchymal Transition and Stemness in Esophageal Carcinoma , 2019, Cells.
[14] K. Yadav,et al. Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. , 2019, Life sciences.
[15] T. Maekawa,et al. Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy. , 2019, Journal of materials chemistry. B.
[16] M. Soukhtanloo,et al. Role of AKT and mTOR Signaling Pathways in the Induction of Epithelial-Mesenchymal Transition (EMT) Process. , 2019, Biochimie.
[17] Yihan Yang,et al. NKCC1 promotes EMT‐like process in GBM via RhoA and Rac1 signaling pathways , 2018, Journal of cellular physiology.
[18] J. Frasor,et al. Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer , 2018, Oncogenesis.
[19] Zhiming Liu,et al. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. , 2018, Oncology reports.
[20] A. Elia,et al. New Directions in the Treatment of Glioblastoma , 2018, Seminars in Neurology.
[21] S. Lipton,et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.
[22] S. Lipton,et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.
[23] Leland S. Hu,et al. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.
[24] Fei-Fei An,et al. Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery , 2017, Theranostics.
[25] William A Weiss,et al. Inhibiting 4EBP1 in Glioblastoma , 2017, Clinical Cancer Research.
[26] K. Williams,et al. Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division* , 2016, The Journal of Biological Chemistry.
[27] Junhui Liu,et al. Systemic delivery to central nervous system by engineered PLGA nanoparticles. , 2016, American journal of translational research.
[28] M. Giorgio,et al. A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deficits , 2015, Neurobiology of Disease.
[29] Yunhui Liu,et al. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. , 2015, Oncology reports.
[30] D Andrews,et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.
[31] N. Bernardes,et al. Bacterial proteins and peptides in cancer therapy , 2014, Bioengineered.
[32] Xiangyan Li,et al. Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling , 2014, Molecular Cancer Therapeutics.
[33] Matthew E. Welsch,et al. Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.
[34] V. Préat,et al. PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[35] D. Majumdar,et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells , 2009, Molecular Cancer Therapeutics.
[36] M. Magzoub,et al. Cancer targeting peptides , 2019, Cellular and Molecular Life Sciences.
[37] A. Walch,et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. , 2017, Nature chemical biology.
[38] Sudesh Kumar Yadav,et al. Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.